The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Lecanemab: Appropriate Use Recommendations
Open accessAbstract
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. Appropriate Use Recommendations (AURs) are intended to help guide the introduction of new therapies into real-world clinical practice. Community dwelling patients with AD differ from those participating in clinical trials. Administration of lecanemab at clinical trial sites by individuals experienced with monoclonal antibody therapy also differs from the community clinic-based administration of lecanemab. These AURs use clinical trial data as well as research and care information regarding AD to help clinicians administer lecanemab with optimal safety and opportunity for effectiveness. Safety and efficacy of lecanemab are known only for patients like those participating in the phase 2 and phase 3 lecanemab trials, and these AURs adhere closely to the inclusion and exclusion criteria of the trials. Adverse events may occur with lecanemab including amyloid related imaging abnormalities (ARIA) and infusion reactions. Monitoring guidelines for these events are detailed in this AUR. Most ARIA with lecanemab is asymptomatic, but a few cases are serious or, very rarely, fatal. Microhemorrhages and rare macrohemorrhages may occur in patients receiving lecanemab. Anticoagulation increases the risk of hemorrhage, and the AUR recommends that patients requiring anticoagulants not receive lecanemab until more data regarding this interaction are available. Patients who are apolipoprotein E ε4 (APOE4) gene carriers, especially APOE4 homozygotes, are at higher risk for ARIA, and the AUR recommends APOE genotyping to better inform risk discussions with patients who are lecanemab candidates. Clinician and institutional preparedness are mandatory for use of lecanemab, and protocols for management of serious events should be developed and implemented. Communication between clinicians and therapy candidates or those on therapy is a key element of good clinical practice for the use of lecanemab. Patients and their care partners must understand the potential benefits, the potential harms, and the monitoring requirements for treatment with this agent. Culture-specific communication and building of trust between clinicians and patients are the foundation for successful use of lecanemab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lecanemab has a boxed warning for serious and symptomatic ARIA and requires testing for APOE ε4 prior to initiation as homozygosity increases risk.(510)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [510]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, anti-amyloid monoclonal antibodies require the confirmation of amyloid-β pathology from PET or CSF before initiating therapy45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, although patients with early-stage AD may be candidates for anti-amyloid therapies15–17, the coexistence of pathology from other etiologies, such as VD, can increase the risk of amyloid-related imaging abnormalities18.”
From AI-based differential diagnosis of dementia etiologies on multimodal data (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The risk of developing these potentially serious adverse effects is higher in APOEε4 carriers, particularly homozygotes, and current recommendations are that patients are genotyped for APOE before starting these therapies to offer a balanced benefit–risk discussion190.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [190]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma biomarkers may therefore have an important role in reducing the patient burden associated with the initiation of anti-amyloid-β therapies for AD, which at present require biomarker confirmation with PET or CSF, as well as serial magnetic resonance imaging to monitor for adverse events45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Individuals with two copies of the APOE‐e4 gene are at increased risk of developing ARIA.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, ApoE genotyping is now increasingly considered an important component of the pre-treatment work-up for anti-amyloid therapies [5, 8, 11, 12].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationMR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging
Fazekas, F., Chawluk, J. B., Alavi, A. A., Hurtig, H. I., & Zimmerman, R. A. (1987) · American Journal of Roentgenology · doi:10.2214/ajr.149.2.351 · Cited by 5,327
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Irizarry M, van Dyck C, Sabbagh M, Bateman RJ, S. C, editors. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer's disease. 15th Clinical Trials on Alzheimer's Disease Conference; 2022; San Francisco, CA USA.
Cited by
Sorted by citations
Items 901–961 of 961
Kaser, A. N., Stricker, J. L., Hughes, M. A., Corriveau‐Lecavalier, N., Boots, E. A., Machulda, M. M., Fields, J. A., Jones, D. T., McCarter, S. J., Botha, H., et al. (2026) · medRxiv · doi:10.64898/2026.09.15.26362283
Operationalizing Alzheimer's disease trials in the era of targeted therapies
Pillai, J. A., Alladi, S., Appleby, B. S., Brosch, J. R., Frederiksen, K. S., Galasko, D. R., López, O. L., Leverenz, J. B., Saykin, A. J., Schott, J. M., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71829
Lee, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187329
Haller, S., Barkhof, F., & Oliveira, T. G. (2026) · Springer eBooks · doi:10.1007/978-3-319-61423-6_64-2
Liu, K., Yang, X., & Kong, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1955230
Cognition in Cardiovascular Disease
Salardini, A., & Azarbar, S. (2026) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-026-01519-w
Katteri, S., Wilks, H., Welhaf, M., Aschenbrenner, A. J., Frank, C. C., Vila‐Castelar, C., Stout, S., Sliwinski, M. J., Benzinger, T. L. S., Clarens, M. F., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71872
Ho, B., & Yang, Y.-H. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2734618
Locally deployed large language model for real‐world lecanemab eligibility pre‐screening
Miklitz, C., Shrestha, M., Wegner, P., Henk, N., Sprinkart, A. M., Block, W., Luetkens, J. A., Radbruch, A., Lehnen, N. C., & Nowak, S. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70495
From bilingual dementia screening to equitable clinical action in primary care
Fujiwara, Y. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261491982
Motolese, F., Ursini, F., Norata, D., Capone, F., Sapio, E., Giesi, M. L. D., Selvaggi, S. A., Annesi, G., Rossi, M., Calandrelli, R., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261488813
Mukherjee, S., Barthélemy, N. R., Atri, T. E., Wang, Q., Yen, D. P., He, Y., Coyle, R. A., Ovod, V., Franklin, E. E., Xiong, C., et al. (2026) · medRxiv · doi:10.64898/2026.09.22.26363432
Morbelli, S. D., Brendel, M., Tolboom, N., Drzezga, A. E., Janelidze, S., Joie, R. L., Roccatagliata, L., Agosta, F., Arbizu, J., Boccalini, C., et al. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100250
Self-citationIntroduction to PET/MR Imaging
Loftus, J. R., & Shepherd, T. M. (2026) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2026.07.001
Lu, S., Hu, S., Huang, J., Shi, Y., Yu, D., Cao, W., Yin, M., Petersen, J. D., & Huang, B. (2026) · Journal of Medical Internet Research · doi:10.2196/92709
Molecular Neuroimaging in Alzheimer’s Disease
Saluja, K. V., Jindal, S., & Benzinger, T. L. S. (2026) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2026.07.003
Privšek, E., Marseglia, A., Košutić, I., Rosenberg, A., Granberg, T., Kramberger, M. G., Kivipelto, M., & Westman, E. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70472
Schwartz, N. U., Ellingson, T. N., Nguyen, H., Lin, Z., Ashton, N. J., Dage, J. L., Deniz, K., Dietz, C. D., Ljubenkov, P. A., Miller, B. L., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70446
Self-citationBollack, A., Buckley, C. J., Battle, M. R., Smith, R., Stromrud, E., Mattsson, N., Palmqvist, S., Hansson, O., Takemoto, S., March, A., et al. (2026) · NeuroImage Clinical · doi:10.1016/j.nicl.2026.104071
Molecular and genetic basis of alzheimer’s disease and emerging treatment Modalities
Varshney, H., & Siddique, Y. H. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2739332
Ji, H., Yang, Y., Wu, X., & Bao, E. (2026) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2026.1977226
Yan, S., Wang, J., Yan, S., Wang, J., Yang, Y., Guan, Y., Chen, Y., Wang, R., Zhang, J., Chang, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11056936/v1
Wicker, A. L., Courtright-Lim, A., & Tilburt, J. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1953954
de Carvalho, G. M. L. (2026) · LUMEN ET VIRTUS · doi:10.56238/levv17n65-011
Park, J. J., Chung, S. Y., Kim, S. M., & Yoo, H. D. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1844523
Surhan, A., Oad, J., Kumar, B., Memon, S. N., Essrani, C., Muhammad, F., Kashif, S. N., Abbas, S. M. I., Ameen, T. B., Sauleh, A., et al. (2026) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-026-01263-5
Joie, R. L., Lin, M.-P., Wang, Y., Soleimani‐Meigooni, D. N., Ellingson, T. N., Nguyen, H., Blazhenets, G., Fonseca, C. S., Nael, K., Soman, S., et al. (2026) · medRxiv · doi:10.64898/2026.10.03.26364642
Self-citationShao, J., & Lei, Z. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1983962
Qiao, Z., Zhao, X., 王桂红, Li, S., Lian, T., & Ai, L. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261493063
Ghirelli, A., Cecchetti, G., Spinelli, E. G., Gajate, A. M. S., Rugarli, G., Pisano, S., Zamboni, I. A. L., Canu, E., Castelnovo, V., Sibilla, E., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70448
Agosta, F., Cecchetti, G., Ghirelli, A., Spinelli, E. G., Rugarli, G., Pisano, S., Coraglia, F., Gajate, A. M. S., Vezzulli, P. Q., Calloni, S. F., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70401
Anti-Amyloid-Antikörper gegen Alzheimer
Oberstein, T. J. (2026) · Der Nervenarzt · doi:10.1007/s00115-026-02024-8
Joshi, H. (2026) · International Journal of Community Pharmacy · doi:10.65301/ijcp.2026.8.3.1
Polygenic Risk Scores in Alzheimer’s Disease: A Cross-Scale View from Genes to Brain and Behavior
Angelopoulou, E., Stamelos, I. G., Sampatakakis, S. N., Papageorgiou, S. G., Scarmeas, N., Hatzimanolis, A., Proukakis, C., & Villa, C. (2026) · Biology · doi:10.3390/biology15201805
Smitasiri, T., Pongpitakmetha, T., Thanprasertsuk, S., & Likitjaroen, Y. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261493065
ApoE lipidation state directs immunometabolic reprogramming of human microglia
Shiferaw, T., Sarkar, S., Baker, K. M., Wooldridge, R., Binfet, H. M., Prozapas, V. N., Ogbu, C. P., Schepmoes, A. A., Attah, I. K., Niemeyer, C. S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71882 · Cited by 1
Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?
Exalto, L. G., van Alphen, J. L., Barkhof, F., Teunissen, C. E., Vijverberg, E. G. B., Aarsland, D., & Lemstra, A. W. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71907
Hill, C., Michopoulou, S. K., Niranjan, M., & Kipps, C. (2026) · medRxiv · doi:10.64898/2026.10.12.26365339
Salinas-López, F. (2026) · Aging & Mental Health · doi:10.1080/13607863.2026.2740017
Intracranial metastasis as a mimic of amyloid-related imaging abnormalities
Hwang, J., Delman, B. N., & Naasan, G. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09449-8
Benussi, A., Agosta, F., Agnello, L., Alfano, A. R., Altini, M., Antico, A., Basilico, S., Bellelli, G., Bonanni, L., Bottini, G., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100685
Engineered antibodies: the molecular workhorses of the immune system as therapeutics
Singh, A., Shadangi, S., Bag, S., & Rana, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44536-1.00017-1
Kujuro, Y., Saito, M., Maruko, M., Kamiyama, K., Nakano, A., Qian, E., Okamura, T., Ito, D., Kageyama, T., Sugiyama, I., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100686
Navigating medication management in dementia care: caregiver experiences and resource needs
Irons, S., Kessler, D., Ghahari, S., & Fakolade, A. O. (2026) · Disability and Rehabilitation · doi:10.1080/09638288.2026.2747161
Jacquier‐Sarlin, M. R., Seignobos, M., Rauzier, L., Schaack, B., Laurin, D., & Buisson, A. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1963040
Maerean, N., Litchev, S., Jackson, G. R., Kass, J. S., Pavlik, V., & Lin, C.-Y. R. (2026) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000761
Rosenberg, A., Rennie, A., Ekman, U., Daniilidou, M., Hall, A., Matton, A., Solomon, A., Wahlund, L., Kivipelto, M., & Westman, E. (2026) · European Journal of Neurology · doi:10.1111/ene.70786
Interpreting the evidence and clinical implementation of anti-Aβ therapies in Alzheimer’s disease
Cui, R.-P., Jiang, Y.-T., & Xu, J. (2026) · Medicine Plus · doi:10.1016/j.medp.2026.100174
He, Z., Zeng, J., Wang, G., Li, Y., & Zhang, F. (2026) · MedComm · doi:10.1002/mco2.71090
van der Veere, P. J., Broulíková, H. M., Hoogland, J., Handels, R. L. H., Vijverberg, E. G. B., van Harten, A. C., Teunissen, C. E., Barkhof, F., van de Giessen, E., van der Flier, W. M., et al. (2026) · European Journal of Epidemiology · doi:10.1007/s10654-026-01470-7
Mohammadi, S., Sharbafshaaer, M., Pirozzi, M. A., Trojsi, F., Ghaderi, S., Iturria‐Medina, Y., & Fereshtehnejad, S.-M. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.2005174
Anticorps monoclonaux anti-amyloïde dans la maladie d’Alzheimer
Lebouvier, T. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.09.002
Choi, W., & Ko, P. (2026) · Brain Sciences · doi:10.3390/brainsci16111161
Tang, L., Chen, X., Zhang, L., Fan, L., Chen, N., Li, C., Cai, Z., Chen, G., Chen, H., Ye, M., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71936
Unschuld, P. G. (2026) · Advances in magnetic resonance technology and applications · doi:10.1016/b978-0-443-21425-7.00014-2
Tabaac, B. J., & Thottempdui, N. (2026) · Clinical nuclear medicine open. · doi:10.1097/nm9.0000000000000099
Achour, B., El‐Khateeb, E., Sierra, T., Terrier, J., Rostami‐Hodjegan, A., & Polasek, T. M. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_854
Current capacity of Portuguese specialized dementia centers in the era of anti‐amyloid antibodies
Tábuas‐Pereira, M., Silva‐Spínola, A., Agostinho, C., Alves, L., Araújo, R., Bernardes, C., Branco, M., Borbinha, C., Cabreira, V., Costa, S., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70513
Cost‐effectiveness of lecanemab for early Alzheimer's disease in China
Zhao, X., Xu, M., Chen, H., Lei, Z., Yu, Q., Liu, J., & Liao, W. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71941
Bermudez, C. L., Pillai, J. J., Burkett, B. J., McDonald, J. S., Johnson, D. R., Wiste, H. J., Weigand, S. D., Jack, C. R., Vemuri, P., Petersen, R. C., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70524
Self-citation
Metadata
- Authors
- Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S.
- Affiliations
- Indiana University Indianapolis (US)
- University of California, San Francisco (US)
- Banner Health (US)
- University of Southern California (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Brown University (US)
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 10
- Issue
- 3
- Pages
- 362-377
- ISSN
- 2274-5807 (ISSN-L)
- PMC
- PMC10313141
- OpenAlex
- W4360591479
- Cited by
- 961
- References
- 62
- Citations by year
- 2026: 335 · 2025: 305 · 2024: 249 · 2023: 71
- FWCI
- 170.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Journal of Prevention of Alzheimer s Disease (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Foundation for the National Institutes of Health (R35AG71476, U01NS093334, P20GM109025, P30AG072959, P30 AG010133, R01AG053798, R01 AG057739)
- Alzheimer's Association (P30 AG010133)
- Alzheimer's Drug Discovery Foundation (P20GM109025)
- Eli Lilly and Company (P20GM109025)
- Biogen (P20GM109025)
- University of Southern California (P20GM109025)
- Patient-Centered Outcomes Research Institute
- Alnylam Pharmaceuticals
- BioClinica (P20GM109025)
- Sunovion
- Buck Institute for Research on Aging
- Prothena
- University of Oxford
- Eisai (P20GM109025)
- Novo Nordisk
- Shionogi
- H. Lundbeck A/S (P20GM109025)
- Grifols
- Nestec
- National Institutes of Health (RD005665)
- Genentech (P20GM109025)
- Allergan
- Avid Radiopharmaceuticals
- National Institute on Aging (AG010133, P30AG010133, U01AG057195, NIA U01 AG057195, R01AG053798, P20AG068053, NIA P30 AG010133, R01AG057739, R35AG71476, P30AG072959, P30AG072980, R35AG071476)
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- lecanemab, Alzheimer's disease, amyloid-related imaging abnormalities, amyloid plaques, mild cognitive impairment, early Alzheimer's disease, bleeding risk, anticoagulation, infusion reactions, monoclonal antibody therapy, caregiver-patient communication, clinical preparedness
- MeSH terms
- Alzheimer Disease, Amyloid, Antibodies, Monoclonal, Humans, Apolipoprotein E4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
